Global Reports of Myocarditis Following COVID-19 Vaccination: A Systematic Review and Meta-Analysis

Sirwan Khalid Ahmed<sup>a,b,c,d</sup>., Mona Gamal Mohamed<sup>e</sup>., Rawand Abdulrahman Essa<sup>a,b,c,d</sup>., Eman Abdelaziz Ahmed Rashad<sup>e</sup>., Peshraw Khdir Ibrahim<sup>f</sup>., Awat Alla Khdir<sup>a,c</sup>., Zhiar Hussen Wsu<sup>a,c</sup> Affiliations

<sup>a</sup> Department of Emergency, Rania Teaching Hospital, Rania, Sulaimani, Kurdistan-region, Iraq

<sup>b</sup> Department of Cardiothoracic and Vascular Surgery, Rania Medical City Hospital, Rania, Sulaimani, Kurdistan-Region, Iraq

<sup>c</sup> Department of Emergency, Rania Pediatric & Maternity Teaching Hospital, Rania, Sulaimani, Kurdistanregion, Iraq

<sup>d</sup> Department of Biotechnology, Institute of Science and Modern Technology, Rojava University, Qamishlo, Syria

<sup>e</sup> Department of Adult Nursing, RAK Medical and Health Sciences University, Ras Al Khaimah, UAE <sup>f</sup>Department of Nursing, University of Raparin, Sulaimani, Rania, Kurdistan-region, Iraq

## **Corresponding Author:**

# Sirwan Khalid Ahmed

Department of Emergency, Rania Teaching Hospital, Rania 46012, Kurdistan region-Iraq, and Department of Biotechnology, Institute of Science and Modern Technology, Rojava University, Qamishlo, Syria

TEL: +9647501553224

# Email: <a href="mailto:sirwan.ahmed1989@gmail.com">sirwan.ahmed1989@gmail.com</a>

## Abstract

In December 2020, the FDA granted emergency approval to Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccines. There have been recent media reports of myocarditis after receiving COVID-19 vaccines, particularly the messenger RNA (mRNA) vaccines, causing public concern. This review summarizes information from published case series and case reports, with a strong emphasis on reporting patient and disease characteristics, investigation, and clinical outcome, to provide a comprehensive picture of the condition. Forty studies, including 147 cases, participated in this systematic review. The median age was 28.9 years; 93.9% were male and 6.1% were female. 72.1% of patients received the Pfizer-BioNTech (BNT162b2) vaccine, 24.5% of patients received the Moderna COVID-19 Vaccine (mRNA-1273), and the rest of the 3.3% received other types of vaccines. Furthermore, most myocarditis cases (87.1%) occurred after the second vaccine dose, after a median time interval of 3.3 days. The most frequently reported symptoms were chest pain, myalgia/body aches and fever. Troponin levels were consistently elevated in 98.6%. The admission ECG was abnormal in 88.5% of cases, and the left LVEF was lower than 50% in 26.5% of cases. The vast majority of patients (93.2%) resolved symptoms and recovered, and only 3 patients died. These findings may help public health policy to consider myocarditis in the context of the benefits of COVID-19 vaccination as well as to assess the cardiac condition before the choice of vaccine, which is offered to male adults. In addition, it must be carefully weighed against the very substantial benefit of vaccination.

## Keywords

COVID-19, Myocarditis, COVID-19 Vaccines, mRNA vaccine, pericarditis

# Introduction

International efforts to drive vaccinations are critical to restoring health and attempting economic and social recovery as the SARS-CoV-2 coronavirus (COVID-19)-caused pandemic continues [1]. The COVID-19

vaccines developed by Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) were granted emergency approval by the Food and Drug Administration (FDA) of the United States in December 2020. Reports of myocarditis after the COVID-19 vaccination, notably after the messenger RNA (mRNA) vaccines, have received widespread media attention in recent months, causing widespread concern among the general public [1]. Myocarditis is diagnosed in about ten to twenty people per 100,000 in the general population each year, and it has been shown to be more common in men and younger age groups [2]. Myocarditis following mRNA vaccination was first reported in Israel in April 2021, and then several case reports and case series were reported around the world.

Specifically, this report examines the current literature on myocarditis following COVID-19 vaccination, summarizing available information from previously published case reports and case series, with a strong attention on reporting patient and disease characteristics, as well as investigation and clinical outcome, in order to provide a comprehensive picture of the condition.

## Methods

#### **Review objectives**

The main objective is to clarify the potential occurrence of myocarditis associated with COVID-19 vaccination and elaborate on the demographic and clinical characteristics of COVID-19 vaccinated individuals who develop myocarditis and how many cases have been reported in the literature.

# **Protocol and Registration**

The review is written in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines for the systematic review of available literature [3]. The protocol of the review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) with ID CRD42022308997. The AMSTAR-2 checklist was also used to evaluate this study, and it was found to be of high quality [4]. This review article didn't need to get ethics approval.

### Search strategy

A comprehensive search of major electronic databases (PubMed and Google Scholar) was conducted on February 10, 2022, to locate all publications. The AND operator was used to connect two of the most important concepts in the search terminology ("COVID-19" AND "Myocarditis"). ("Myocarditis" and "COVID-19" OR "SARS-CoV-2" OR "Coronavirus Disease 2019" OR "severe acute respiratory syndrome coronavirus 2" OR "coronavirus infection" OR "2019-nCoV" AND "vaccine, vaccination, OR vaccine" were used in the search. To make sure the search was completed, we checked the references of all relevant papers.

# **Eligibility criteria**

All case series and case reports on post-COVID-19 vaccine myocarditis in humans were included. Individuals who develop myocarditis after receiving the COVID-19 vaccine, regardless the type of vaccine and dose. The references of the relevant articles will also be reviewed for additional articles that meet the inclusion criteria. Narrative and systematic reviews, original and unavailable data papers were excluded in this review. Moreover, articles other than English were excluded in this review.

## Data extraction and selection process

PRISMA 2020 was used to guide every step of the data extraction process from the original source. The Rayyan website was used by two independent authors (SKA and RAE) to screen abstracts and full-text articles based on inclusion and exclusion criteria [5]. The third author (RAE) resolved any discrepancies between the two independent authors. Microsoft Excel spreadsheets were used to collect the necessary information from the extracted data. Author names, year of publication, age, gender, type of COVID-19 vaccine, dose, days to symptoms onset, symptoms, troponin level, LVEF 50% or LVEF > 50%, ECG, length of hospital stay/days, treatment, and outcomes were extracted from each study.

# **Critical appraisal**

To assess the quality of all included studies, we used the Joanna Briggs Institute's critical appraisal tool for case series and case reports [6]. Each article was evaluated by two different authors (SKA and RAE), each of whom worked independently. Paper evaluation disputes were resolved either through discussion or by a third author (RAE) depending on the circumstances. Articles with an average score of 50 percent or higher were included in the data extraction process. The AMSTAR 2 criteria [4]. were used to evaluate the results of our systematic review. The AMSTAR 2 tool assigned a "medium" rating to the overall quality of our systematic review.

### Data synthesis and analysis

All the articles included in the current systematic review were analysed, and the data was extracted and pooled. This included (authors' names, year of publication; gender; type of COVID-19 vaccine, dose, days to symptoms onset, troponin level, LVEF below or above 50%, ECG, length of hospital stay/days; treatment and outcomes). We gathered this data from the results of eligibility studies. COVID-19 vaccine recipients who developed myocarditis were included in the study.

## Results

# Selection of studies

When we searched the major databases (PubMed and Google Scholar) on February 10, 2022, we discovered 2712 articles that were relevant to our search criteria. A citation manager tool (Mendeley) was then used to organize the references, and 283 articles were automatically removed because they contained duplicate content. Next, the titles, abstracts, and full texts of 2429 articles were checked for accuracy, and 2365 articles were rejected because they did not meet the criteria for inclusion. Besides that, 64 articles were submitted for retrieval, but twenty-four were rejected because they did not meet our inclusion requirements. The current systematic review was limited to 40 articles in total (**Fig 1**). The details of case reports and case series are shown in (**Table 1**).

#### Characteristics of the included studies

Overall, forty studies, including 147 cases each, from the United States, Italy, Israel, Germany, Poland, France, Korea, Brazil, Japan, Mexico, and Iran participated in this systematic review. The median age was 28.9 years; 93.9% were male and 6.1% were female. 72.1% of patients received the Pfizer-BioNTech (BNT162b2) vaccine, 24.5% of patients received the Moderna COVID-19 Vaccine (mRNA-1273), and the rest of the 3.3% received other types of vaccines (Johnson & Johnson, AstraZeneca, Sinovac).

The vast majority of cases are from the United States. All patients were diagnosed with myocarditis or myopericarditis following COVID-19 vaccination, regardless of the type of vaccine and dose.

Furthermore, most myocarditis cases (87.1%, n = 128) occurred after the second vaccine dose, after a median time interval of 3.3 days. The most frequently reported symptoms were chest pain (100% n = 147), fever (46.9% n = 69), myalgia/body aches (54.4% n = 80), and also variable reports of viral prodromes such as chills, headaches, and malaise. Troponin levels were consistently elevated in 98.6% (n = 145) of the cases where they were reported, consistent with myocardial injury. The admission electrocardiogram (ECG) was abnormal in 88.5% (n = 130) of cases, and the left ventricular ejection fraction (LVEF) was lower than 50% in 26.5% (n = 39) of cases. The median length of hospital stay was 5.2 days in 127 patients but unknown in 20 patients. The vast majority of patients (93.2%) (n = 137) resolved symptoms and recovered, and only 3 patients died (**Table 2**).

# Discussion

The current systematic review summarized evidence from the original case reports and case series that explored the development of myocarditis after COVID-19 vaccination. Throughout the selected studies, most of the participants were male, from the USA, and their mean age 28.94 was years old. The mechanism of vaccine-induced myocarditis is not known but may be related to the active pathogenic component of the vaccine and specific human proteins, which could lead to immune cross-reactivity resulting in autoimmune disease, which is

one cause of myocarditis [7–10]. The occurrence of myocarditis in men may be related to sex hormone variations, as testosterone hormone suppresses anti-inflammatory immune cells while promoting more aggressive T helper cells [7,11].

These findings were matched with Oster et al (2022) [12], who found the incidence rate of myocarditis among vaccinated male people was similar to that seen in typical cases of myocarditis and there was a strong male predominance for both conditions [13]. Fatima et al (2022) [7] found most patients who developed myocarditis were males. Moreover, Patone et al (2022) [14] mentioned that the incidence of myocarditis was among England males younger than 40 years old. Similarly, a systematic review study found that the Incidence of myocarditis following mRNA vaccines is low but probably highest in males aged 12-29 years old [15].

Another important finding in the current systematic review is that most of the participants received Pfizer-BioNTech (BNT 162b2) followed by the Moderna CVID-19 vaccine (mRNA-1273), and most of the cases who complained of myocarditis received two doses of the vaccine. This indicates that mRNA vaccines are associated with a higher risk of developing myocarditis than viral vector vaccines, including Janssen, Oxford, and Sinovac. Bozkurt et al (2021) [2], have assumed that autoantibody generation could attack cardiac myocytes in response to mRNA vaccine, which increases the risk.

This finding is matched with Patone (2022) [14], who mentioned the risk of myocarditis increased within a week of receiving the first dose of both adenovirus and mRNA vaccines and after the second dose of mRNA vaccine. Oster et al (2022) [12] concluded that the risk of myocarditis after the mRNA vaccine was increased after the second dose in adolescents and young males. On the other hand, Simone et al (2021) [16] concluded that there is no relationship between COVID-19 mRNA vaccination and post vaccination myocarditis.

The findings extend these observations, which include the median onset of symptoms after vaccine administration was 3.32 days. The most common symptoms are chest pain, followed by myalgia/ body aches and fever. These findings matched with Pillay et al (2021) [15], who reported in a systematic review observation that the majority of myocarditis cases had a short symptoms onset of 2 to 4 days after a second dose, and the

majority presented with chest pain. These findings matched with Oster et al (2022) [12], who mentioned myocarditis was diagnosed within days of vaccination.

In patients with severe myocarditis, the diagnosis is often established by heart biopsy. In patients with mild myocarditis, the diagnosis is based on compatible clinical findings and confirmed by elevated levels of blood markers or an electrocardiogram (ECG) indicative of cardiac injury, with the presence of new abnormalities on echocardiography or cardiac MRI [17].

Cardiac-specific investigations revealed that troponin levels were elevated in almost all of the cases, consistent with myocardial injury, which is associated with autoimmune processes matched with vaccine protein and the case immune system.

In the same line with Lee et al. (2022) [1], a systematic review to investigate myocarditis following COVID-19 Vaccination in October 2020–October 2021, mentions that all reported cases have an elevated troponin level in keeping with myocardial injury.

In our study, less than one third of cases had left ventricle ejection friction (LVEF) was less than 50%. Compared to patients with COVID-19 illness, patients with vaccine associated myocarditis had a higher LVEF.

This finding is consistent with the findings of Fronza et al. (2022) [18], who investigated myocardial injury patterns at MRI in COVID-19 Vaccine and discovered that more than half of the cases had more than 50% LVEF. Also, Shiyovich et al. (2022) [19], who analyzed myocarditis following the third (Booster) dose of COVID-19 vaccination found that the mean left ventricular ejection fraction was  $61 \pm 7\%$  (range 53–71%) and regional wall motion abnormalities were present in one of the patients only. Global T1 values were increased in one (25%) of the patients, while focal values were increased in 3 (75%) of the patients (100%). Global ECV was increased in 3 (75%) of the patients, while focal values were increased in all the patients (100%). LGE was present in all the patients.

In our systematic review and meta-analysis study, 88.5% of cases had abnormal changes in the electrocardiogram (ECG) result, regardless of the vaccine type.

Vidula et al. (2021) [20] support our findings by reporting two patients with clinically suspected myocarditis who presented with acute substernal chest pain and/or dyspnea after receiving the second dose of the vaccine and were found to have diffuse ST elevations on electrocardiogram (ECG), elevated cardiac biomarkers and inflammatory markers, and mildly reduced left ventricular (LV) function on echocardiography.

Also, Puchalski et al. [21] reported the findings of a case series regarding COVID-19-Vaccination-Induced Myocarditis in Teenagers. Electrocardiogram (ECG) patterns varied, but in all cases, characteristic features of acute myocardial injury, including ST segment elevation or depression, and repolarization time abnormalities, were present.

Management of myocarditis remains largely supportive and is based on the restoration of hemodynamic stability and the administration of guideline-directed heart failure and arrhythmia treatment. Patients with preserved ventricular function and non- severe features were often treated with colchicine or non- steroidal anti-inflammatory drugs. According to our findings, all cases were treated with NSAIDs, beta blockers, calcium channel blockers, and/or diuretics. The median length of hospital stay was 5.2 days in 127 patients, and the vast majority of patients resolved symptoms and recovered, and only 3 patients died.

This finding broadly supports the work of other studies in this area. Woo et al [22] reported that many patients who received anti-inflammatory agents such as NSAIDs, colchicine, steroids, and intravenous immunoglobulin recovered without further medical treatment, with a hospital stay lasting 3-6 days.

In accordance with the present results, previous studies have demonstrated that almost all of the cases experienced a prompt recovery with no residual cardiac dysfunction. The median length of stay for all myocarditis cases was around 2-3 days, with a range of 2-10 days [23].

## Conclusion

In conclusion, these findings may help public health policy to consider myocarditis in the context of the benefits of COVID-19 vaccination as well as to assess the cardiac condition before the choice of vaccine, which is offered to male adults. In addition, it must be carefully weighed against the very substantial benefit of vaccination. Moreover, further research is required to assess the long-term consequences and other risk factors following immunization, specifically the mRNA-1273 vaccine.

# **Conflicts of interest**

There is no conflict to be declared.

## Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-forprofit sectors.

## **Author Agreement Statement**

We declare that this manuscript is original, has not been published before and is not currently being considered for publication elsewhere. We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We confirm that the order of authors listed in the manuscript has been approved by all of us. We understand that the Corresponding Author is the sole contact for the Editorial process. He is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs.

#### Data availability Statement

All relevant data are within the manuscript and its supporting information files.

Authors' contributions: Conception and design SKA acquisition of data SKA, RAE, MGM, EAA analysis and interpretation of data SKA, MGM, RAE, EEA, drafting of the manuscript SKA, RAE, MGM, EAA, PKI critical revision of the manuscript for important intellectual content statistical analysis SKA, MGM, RAE, EEA, PKI,

AAK, ZHW administrative SKA, MGM, EAA technical SKA, AAK, ZHW, supervision SKA, RAE and all authors approving final draft.

#### **Provenance and peer review**

Not commissioned, externally peer-reviewed

## Acknowledgments

Not applicable

## References

- [1] A.S.Y. Lee, D.D. Iswaree, O. Balakrishnan, C.Y. Khoo, C.T. Ng, J.K.X. Loh, L.L. Chan, L.L.Y. Teo, D.K.L. Sim, Myocarditis Following COVID-19 Vaccination: A Systematic Review (October 2020–October 2021), Hear Lung Circ. (2022) S1443-9506.
  https://doi.org/https://doi.org/10.1016/j.hlc.2022.02.002.
- B. Bozkurt, I. Kamat, P.J. Hotez, Myocarditis with COVID-19 mRNA vaccines, Circulation. 144 (2021)
  471–484.
- M.J. Page, J.E. McKenzie, P.M. Bossuyt, I. Boutron, T.C. Hoffmann, C.D. Mulrow, L. Shamseer, J.M. Tetzlaff, E.A. Akl, S.E. Brennan, The PRISMA 2020 statement: an updated guideline for reporting systematic reviews, Int J Surg. 88 (2021) 105906.
  https://doi.org/https://doi.org/10.1016/j.ijsu.2021.105906.
- [4] B.J. Shea, B.C. Reeves, G. Wells, M. Thuku, C. Hamel, J. Moran, D. Moher, P. Tugwell, V. Welch, E. Kristjansson, AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both, Bmj. 358 (2017).
- [5] M. Ouzzani, H. Hammady, Z. Fedorowicz, A. Elmagarmid, Rayyan—a web and mobile app for systematic reviews, Syst Rev. 5 (2016) 1–10.

- [6] S. Moola, Z. Munn, C. Tufanaru, E. Aromataris, K. Sears, R. Sfetcu, M. Currie, R. Qureshi, P. Mattis, K. Lisy, Chapter 7: Systematic reviews of etiology and risk, Joanna Briggs Inst Rev Manual Joanna Briggs Inst. 5 (2017). https://synthesismanual.jbi.global/.
- M. Fatima, H.A. Cheema, M.H.A. Khan, H. Shahid, M.S. Ali, U. Hassan, M.W. Murad, M.A.U.
  Rehman, H. Farooq, Development of myocarditis and pericarditis after COVID-19 vaccination in adult population: A systematic review, Ann Med Surg. (2022) 103486.
- [8] A. Pollack, A.R. Kontorovich, V. Fuster, G.W. Dec, Viral myocarditis—diagnosis, treatment options, and current controversies, Nat Rev Cardiol. 12 (2015) 670–680.
- [9] J.R. Su, Myopericarditis following COVID-19 vaccination: Updates from the Vaccine Adverse Event Reporting System (VAERS), (2021).
- [10] J. Montgomery, M. Ryan, R. Engler, D. Hoffman, B. McClenathan, L. Collins, D. Loran, D. Hrncir, K. Herring, M. Platzer, Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military, JAMA Cardiol. 6 (2021) 1202–1206.
- [11] D. Fairweather, L.T. Cooper Jr, L.A. Blauwet, Sex and gender differences in myocarditis and dilated cardiomyopathy, Curr Probl Cardiol. 38 (2013) 7–46.
- [12] M.E. Oster, D.K. Shay, J.R. Su, J. Gee, C.B. Creech, K.R. Broder, K. Edwards, J.H. Soslow, J.M. Dendy, E. Schlaudecker, Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021, JAMA. 327 (2022) 331–340.
- [13] V. Kytö, J. Sipilä, P. Rautava, The effects of gender and age on occurrence of clinically suspected myocarditis in adulthood, Heart. 99 (2013) 1681–1684.
- [14] M. Patone, X.W. Mei, L. Handunnetthi, S. Dixon, F. Zaccardi, M. Shankar-Hari, P. Watkinson, K. Khunti, A. Harnden, C.A.C. Coupland, Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection, Nat Med. (2021) 1–13.

- [15] J. Pillay, L. Bialy, L. Gaudet, A. Wingert, A. Mackie, D.I. Paterson, L. Hartling, Myocarditis and Pericarditis following COVID-19 Vaccination: Rapid Systematic Review of Incidence, Risk Factors, and Clinical Course, MedRxiv. (2021).
- [16] A. Simone, J. Herald, A. Chen, N. Gulati, A.Y.-J. Shen, B. Lewin, M.-S. Lee, Acute myocarditis following COVID-19 mRNA vaccination in adults aged 18 years or older, JAMA Intern Med. 181 (2021) 1668–1670.
- [17] S. Heymans, L.T. Cooper, Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms, Nat Rev Cardiol. (2021) 1–3.
- [18] M. Fronza, P. Thavendiranathan, V. Chan, G.R. Karur, J.A. Udell, R.M. Wald, R. Hong, K. Hanneman, Myocardial Injury Pattern at MRI in COVID-19 Vaccine–associated Myocarditis, Radiology. (2022) 212559.
- [19] A. Shiyovich, G. Witberg, Y. Aviv, R. Kornowski, A. Hamdan, A Case Series of Myocarditis Following Third (Booster) Dose of COVID-19 Vaccination: Magnetic Resonance Imaging Study, Front Cardiovasc Med. 9 (2022).
- [20] M.K. Vidula, M. Ambrose, H. Glassberg, N. Chokshi, T. Chen, V.A. Ferrari, Y. Han, Myocarditis and other cardiovascular complications of the mRNA-based COVID-19 vaccines, Cureus. 13 (2021).
- [21] M. Puchalski, H. Kamińska, M. Bartoszek, M. Brzewski, B. Werner, COVID-19-Vaccination-Induced Myocarditis in Teenagers: Case Series with Further Follow-Up, Int J Environ Res Public Health. 19 (2022) 3456.
- [22] W. Woo, A.Y. Kim, D.K. Yon, S.W. Lee, J. Hwang, L. Jacob, A. Koyanagi, M.S. Kim, D.H. Moon, J.W. Jung, Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID-19 vaccine, J Med Virol. (2021).
- [23] T. Almas, S. Rehman, E. Mansour, T. Khedro, A. Alansari, J. Malik, N. Alshareef, V.R. Nagarajan, A.H.

Al-Awaid, R. Alsufyani, Epidemiology, clinical ramifications, and cellular pathogenesis of COVID-19 mRNA-vaccination-induced adverse cardiovascular outcomes: A state-of-the-heart review, Biomed Pharmacother. 149 (2022) 112843.

- [24] S.A. Mouch, A. Roguin, E. Hellou, A. Ishai, U. Shoshan, L. Mahamid, M. Zoabi, M. Aisman, N.
  Goldschmid, N.B. Yanay, Myocarditis following COVID-19 mRNA vaccination, Vaccine. 39 (2021)
  3790–3793.
- [25] M. Marshall, I.D. Ferguson, P. Lewis, P. Jaggi, C. Gagliardo, J.S. Collins, R. Shaughnessy, R. Caron, C. Fuss, K.J.E. Corbin, Symptomatic acute myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination, Pediatrics. 148 (2021).
- [26] T. D'Angelo, A. Cattafi, M.L. Carerj, C. Booz, G. Ascenti, G. Cicero, A. Blandino, S. Mazziotti, Myocarditis after SARS-CoV-2 vaccination: a vaccine-induced reaction?, Can J Cardiol. 37 (2021) 1665–1667.
- [27] M. Nassar, N. Nso, C. Gonzalez, S. Lakhdar, M. Alshamam, M. Elshafey, Y. Abdalazeem, A. Nyein, B.
  Punzalan, R.J. Durrance, COVID-19 vaccine-induced myocarditis: case report with literature review,
  Diabetes Metab Syndr. 15 (2021) 102205.
- [28] H.W. Kim, E.R. Jenista, D.C. Wendell, C.F. Azevedo, M.J. Campbell, S.N. Darty, M.A. Parker, R.J.
  Kim, Patients with acute myocarditis following mRNA COVID-19 vaccination, JAMA Cardiol. 6 (2021) 1196–1201.
- [29] A.K. Verma, K.J. Lavine, C.-Y. Lin, Myocarditis after Covid-19 mRNA vaccination, N Engl J Med. 385 (2021) 1332–1334.
- [30] C.M. Rosner, L. Genovese, B.N. Tehrani, M. Atkins, H. Bakhshi, S. Chaudhri, A.A. Damluji, J.A. De Lemos, S.S. Desai, A. Emaminia, Myocarditis temporally associated with COVID-19 vaccination, Circulation. 144 (2021) 502–505.

- [31] A. Dionne, F. Sperotto, S. Chamberlain, A.L. Baker, A.J. Powell, A. Prakash, D.A. Castellanos, S.F. Saleeb, S.D. de Ferranti, J.W. Newburger, Association of myocarditis with BNT162b2 messenger RNA COVID-19 vaccine in a case series of children, JAMA Cardiol. 6 (2021) 1446–1450.
- [32] B. García, P. Ortega, B.F. JA, C. León, R. Burgos, C. Dorta, Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19, Rev Esp Cardiol. 74 (2021) 812–814.
- [33] J.B. Dickey, E. Albert, M. Badr, K.M. Laraja, L.M. Sena, D.S. Gerson, J.E. Saucedo, W. Qureshi, G.P. Aurigemma, A series of patients with myocarditis following SARS-CoV-2 vaccination with mRNA-1279 and BNT162b2, Cardiovasc Imaging. 14 (2021) 1862–1863.
- [34] E. Tano, S. San Martin, S. Girgis, Y. Martinez-Fernandez, C. Sanchez Vegas, Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine, J Pediatric Infect Dis Soc. 10 (2021) 962–966.
- [35] K.F. Larson, E. Ammirati, E.D. Adler, L.T. Cooper Jr, K.N. Hong, G. Saponara, D. Couri, A. Cereda, A. Procopio, C. Cavalotti, Myocarditis after BNT162b2 and mRNA-1273 vaccination, Circulation. 144 (2021) 506–508.
- [36] A. Deb, J. Abdelmalek, K. Iwuji, K. Nugent, Acute myocardial injury following COVID-19 vaccination: a case report and review of current evidence from vaccine adverse events reporting system database, J Prim Care Community Health. 12 (2021) 21501327211029230.
- [37] A. Abbate, J. Gavin, N. Madanchi, C. Kim, P.R. Shah, K. Klein, J. Boatman, C. Roberts, S. Patel, S. Danielides, Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients, Int J Cardiol. 340 (2021) 119–121.
- [38] A. Muthukumar, M. Narasimhan, Q.-Z. Li, L. Mahimainathan, I. Hitto, F. Fuda, K. Batra, X. Jiang, C. Zhu, J. Schoggins, In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-19 mRNA vaccine, Circulation. 144 (2021) 487–498.
- [39] A. Isaak, A. Feisst, J.A. Luetkens, Myocarditis following COVID-19 vaccination, Radiology. 301 (2021)

E378–E379.


- [40] A. Cereda, C. Conca, L. Barbieri, G. Ferrante, G. Tumminello, S. Lucreziotti, M. Guazzi, A. Mafrici, Acute myocarditis after the second dose of SARS-CoV-2 vaccine: Serendipity or atypical causal relationship?, Anatol J Cardiol. 25 (2021) 522.
- [41] K. Watkins, G. Griffin, K. Septaric, E.L. Simon, Myocarditis after BNT162b2 vaccination in a healthy male, Am J Emerg Med. 50 (2021) 815-e1.
- [42] B. Chamling, V. Vehof, S. Drakos, M. Weil, P. Stalling, C. Vahlhaus, P. Mueller, M. Bietenbeck, H. Reinecke, C. Meier, Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis?, Clin Res Cardiol. 110 (2021) 1850–1854.
- [43] J. Mansour, R.G. Short, S. Bhalla, P.K. Woodard, A. Verma, X. Robinson, D.A. Raptis, Acute myocarditis after a second dose of the mRNA COVID-19 vaccine: a report of two cases, Clin Imaging. 78 (2021) 247–249.
- [44] D. Levin, G. Shimon, M. Fadlon-Derai, L. Gershovitz, A. Shovali, A. Sebbag, S. Bader, N. Fink, B.Gordon, Myocarditis following COVID-19 vaccination–a case series, Vaccine. 39 (2021) 6195–6200.
- [45] J. Schauer, S. Buddhe, J. Colyer, E. Sagiv, Y. Law, S.M. Chikkabyrappa, M.A. Portman,
  Myopericarditis after the Pfizer messenger ribonucleic acid coronavirus disease vaccine in adolescents, J
  Pediatr. 238 (2021) 317–320.
- [46] M. Shumkova, D. Vassilev, K. Karamfiloff, R. Ivanova, K. Stoyanova, T. Yaneva-Sirakova, R.J. Gil, Acute myocarditis associated with the Pfizer/BioNTech vaccine, Kardiol Pol (Polish Hear Journal). 79 (2021) 1282–1283.
- [47] P.K. Minocha, D. Better, R.K. Singh, T. Hoque, Recurrence of acute myocarditis temporally associated with receipt of the mRNA coronavirus disease 2019 (COVID-19) vaccine in a male adolescent, J

Pediatr. 238 (2021) 321-323.

- [48] A.A. Hasnie, U.A. Hasnie, N. Patel, M.U. Aziz, M. Xie, S.G. Lloyd, S.D. Prabhu, Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report, BMC Cardiovasc Disord. 21 (2021) 1–6.
- [49] J. Starekova, D.A. Bluemke, W.S. Bradham, T.M. Grist, M.L. Schiebler, S.B. Reeder, Myocarditis associated with mRNA COVID-19 vaccination, Radiology. 301 (2021) E409–E411.
- [50] T. Koizumi, T. Awaya, K. Yoshioka, S. Kitano, H. Hayama, K. Amemiya, Y. Enomoto, Y. Yazaki, M. Moroi, M. Nakamura, Myocarditis after COVID-19 mRNA vaccines, QJM An Int J Med. 114 (2021) 741–743.
- [51] K. McLean, T.J. Johnson, Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: A case report, Acad Emerg Med. 28 (2021) 918–921.
- [52] P.G. Riedel, V.F. Sakai, S. de C.C. Toniasso, M.C.B. Brum, F.S. Fernandes, R.M. Pereira, C.P. Baldin,
  C. de Campos Baldin, A.Y. Takahasi, H. Shiki, Heart failure secondary to myocarditis after SARS-CoV-2 reinfection: a case report, Int J Infect Dis. 113 (2021) 175–177.
- [53] K. In-Cheol, K. Hyungseop, L.H. Jeong, K.J. Yoon, K. Jin-Young, Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination, J Korean Med Sci. 36 (2021) 1–6.
- [54] T.D. Nguyen, G. Mall, J.G. Westphal, O. Weingärtner, S. Möbius-Winkler, P.C. Schulze, Acute myocarditis after COVID-19 vaccination with mRNA-1273 in a patient with former SARS-CoV-2 infection, ESC Hear Fail. (2021).
- [55] N. Azdaki, M. Farzad, Long QT interval and syncope after a single dose of COVID-19 vaccination: a case report, Pan Afr Med J. 40 (2021).
- [56] J.M. Sokolska, J. Kurcz, W. Kosmala, Every rose has its thorns—acute myocarditis following COVID-19 vaccination, Kardiol Pol (Polish Hear Journal). 79 (2021) 1153–1154.

- [57] Y.R. Patel, D.W. Louis, M. Atalay, S. Agarwal, N.R. Shah, Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: a case series, J Cardiovasc Magn Reson. 23 (2021) 1–8.
- [58] D. Kim, J.H. Choi, J.Y. Jang, O. So, E. Cho, H. Choi, K.S. Hong, K.T. Park, A Case Report for Myopericarditis after BNT162b2 COVID-19 mRNA Vaccination in a Korean Young Male, J Korean Med Sci. 36 (2021).
- [59] P. Ehrlich, K. Klingel, S. Ohlmann-Knafo, S. Hüttinger, N. Sood, D. Pickuth, M. Kindermann, Biopsyproven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report, Clin Res Cardiol. 110 (2021) 1855–1859.
- [60] P. Schmitt, R. Demoulin, R. Poyet, E. Capilla, G. Rohel, F. Pons, C. Jégo, S. Sidibe, A. Druelle, F.-X.
  Brocq, Acute Myocarditis after COVID-19 vaccination: A case report, La Rev Med Interne. 42 (2021)
  797–800.
- [61] M. Kadwalwala, B. Chadha, J. Ortoleva, M. Joyce, Multimodality imaging and histopathology in a young man presenting with fulminant lymphocytic myocarditis and cardiogenic shock after mRNA-1273 vaccination, BMJ Case Reports CP. 14 (2021) e246059.
- [62] M. Azir, B. Inman, J. Webb, L. Tannenbaum, STEMI Mimic: Focal Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine, J Emerg Med. 61 (2021) e129–e132.

# Fig 1: PRISMA flow-diagram



# Table 1: Characteristics and outcomes of patients with myocarditis related to COVID-19 vaccine.

Author/Y ear of publicati on	Cou ntry	Age	Gen der	Type of COVID- 19 vaccine	Dose	Days to symptom onset	Symptoms	Troponi n level	LVEF <50% or LVEF >50%	Electroc ardiogr am (ECG)	Treatment	Lengt h of hospit al stay (days)	Outco me
Abu Mouch et al 2021 [24]	Israel	6 cases mean age 22 years	All of them were male	BNT162b 2	2 <sup>nd</sup> in 5 cases and 1 <sup>st</sup> in one case	Mean 4.5 days	Chest pain/discomfort	Elevated in all cases	LVEF >50% in all cases	Abnorm al in all cases	NSAIDs and colchicine	Mean 5.6 days	Recover ed
Marshall et al 2021 [25]	USA	7 cases mean age 16.7 years	All of them were male	BNT162b 2	2 <sup>nd</sup>	Mean 2.57 days	Chest pain	Elevated in all cases	LVEF >50% in 6 cases and LVEF <50% in one case	Abnorm al in all cases	NSAIDs, IVIg, IV methylprednis olone, PO prednisone, famotidine, aspirin	Mean 11.57 days	Recover ed
D'Angelo et al 2021 [26]	Italy	30 years	Male	BNT162b 2	1 <sup>st</sup>	21 days	dyspnea, constrictive retrosternal pain, nausea, and profuse sweating	Elevated	LVEF >50%	Abnorm al	Bisoprolol, aspirin, and prednisolone	7 days	Recover ed
Nassar et al 2021 [27]	USA	70 years	Fema le	Ad26.CO V2. S	1 <sup>st</sup>	2 days	The patient arrived at the emergency department in severe respiratory distress	Elevated	LVEF >50%	Abnorm al	vasopressors and antibiotic therapy	8 days	Died
Kim et al 2021 [28]	USA	4 cases mean age 38.25 years	3 male s and 1 fema le	mRNA- 1273 in 2 cases And BNT162b 2 in 2 cases	2 <sup>nd</sup>	Mean 2.75 days	Chest pain	Elevated in all cases	LVEF >50% in 3 cases and LVEF <50% in one case	Abnorm al in all cases	Corticosteroid s NSAIDs and colchicine	Mean 2.5 days	Recover ed
Montgom ery et al 2021 [10]	USA	23 cases mean age 25 years	All of there were male	BNT162b 2 in 7 cases and 16 cases mRNA- 1273	2 <sup>nd</sup> in 20 cases and 1 <sup>st</sup> in 3 cases	Mean 2 days	Chest pain	Elevated in all cases	LVEF <50% in 4 cases and LVEF ≥50% in 19 cases	Abnorm al in 19 cases and normal in 4 cases	All patients received brief supportive care	Mean 7 days	16 cases were fully recover ed and 7 cases under follow- up
Verma et al 2021 [29]	USA	2 cases (45, 42) years Mean age 43.5 years	1 male and 1 fema le	BNT162b 2- in 1 case and 1 case mRNA- 1273	1 <sup>st</sup> in one case and 2 <sup>nd</sup> in anothe r case	Mean 12 days	Chest pain, dyspnea and dizziness,	Elevated in all cases	LVEF >50% in all cases	Abnorm al in all cases	intravenous diuretics, methylprednis olone, lisinopril, spironolacton e, and metoprolol succinate).	7 days	female case recover ed and male case died
Rosner et al 2021 [30]	USA	7 cases Mean age 27.42 years	All of them were male	BNT162b 2 in 5 cases, one case mRNA- 1273 and one case Ad26.CO V2. S	2 <sup>nd</sup> in 6 cases and 1 <sup>st</sup> in one case	Mean 3.85 days	Chest pain	Elevated in all cases	LVEF >50% in 6 cases and LVEF <50% in one case	Abnorm al in 6 cases and normal in one case	β-blocker and anti- inflammatory medication 20	Mean 2.85 days	Recover ed

$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	al 2021 [31] Garcı'a et al 2021 [32] Dickey et al 2021	Mexi co	cases mean age 15 years 39 years	cases male and one case fema le	2 in all cases BNT162b	all cases	days	myalgia,	in all	<50% in all	al in all	'		Recover ed
[31] age 13 yearsman age 13 (case fema b2 in all cases fema bcases and one case fema b2 in all casescases and age 2cases and age 2cases and age 2cases and age 2cases and age 2cases and age 2cases and age 2cases and age 2cases and age 2cases and age 2cases and and age 2Male bBNT162b a2 <sup>ad</sup> ad age 2Mean 3.33 adys and and age 2Chest pain and age 2Elevated pain, chils, molai, and fever and fever 	[31] Garci´a et al 2021 [32] Dickey et al 2021	со	mean age 15 years 39 years	male and one case fema le	2 in all cases BNT162b	cases						therapy.	2 days	ed
	Garcı´a et al 2021 [32] Dickey et al 2021	со	age 15 years 39 years	and one case fema le	cases BNT162b			neauache	cases	case	cases			
Image: Section of the sectin of the section of the section of the	al 2021 [32] Dickey et al 2021	со	years 39 years	one case fema le	BNT162b	2nd								
Game in al 2021 [32]Mexic pearsSame pearsMale pearsBNT162b pears $2^{ad}$ pearsMean 3.3 pearsChest pain pin, chills, mean datElevated pin, chills, mean datLVEF pearsAbnorm alAbnorm alManormal pears6 days102koy et al 2021 [33]USA pears6 cases mean age 27 years'All mean pearsBNT162b them pears $2^{ad}$ pearsMean 3.3 dayschest pears, head and feverElevated pears, pears, head pears, pears, pears, pears, pears,Mean 2.2 pears, pears, pears, pears, pears, pears, pears, pears, pears,SNT162b them pears, pears, pears, pears, pears, pears, pears,Mean 2.2 pears, pears, pears, pears, pears, pears,Mean 2.2 pears, pears, pears, pears, pears, pears, pears, pears, pears,All pears, pears, pears, pears, pears, pears, pears,BNT162b pears, pears, pears, pears, pears, pears,Mean 2.2 pears, pears, pears, pears, pears, pears, pears,All pears, pears, pears, pears, pears, pears,All pears, pears, pears, pears, pears, pears,All pears, pears, pears, pears, pears, 	al 2021 [32] Dickey et al 2021	со	39 years	case fema le		2nd								
	al 2021 [32] Dickey et al 2021	со	years	le		2nd								
	al 2021 [32] Dickey et al 2021	со	years			2.nd								
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	al 2021 [32] Dickey et al 2021	со	years	Male		2 <sup>nd</sup>								
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	[32] Dickey et al 2021		-			-	<sup>1</sup> ⁄4 day	Chest pain	Elevated				6 days	Recover
	Dickey et al 2021	USA	6 cases		2					>50%	al			ed
al 2021 [33]mean age 27 yearsof them were maleBNT 162b 2 in 5 cases and one casedays and epain, chills, mydgia, malaise, headache and feverin all cases and fever>50% in 3 cases cases and cases and casesall 5 cases and normal casesownTano et al 2021 [34]USA age (16.6] yearsScases and one casesAll and cases2"a in 7 cases and casesMean 2. cases and and feverChest pain, fatigue, abdominal pain, or breathElevated in all casesLVEF and all in 6 casesAbnorm all in 6 casesNSAIDs daysMean 2.36 daysLarson et 	al 2021	USA	o cases	A 11		Ond	Maam 2 22	ahaat	Elevated	LVEE	Ahnorm		Unite	Recover
[33]age 27them years2 in 5 and male2 in 5 cases and one case mRNA-myalgia, malaise, headache and fevercasescases headache and fevercasescases cases and headache and fevercasescases casescases headache and fevercasescases casesden responsecases and normal casescases normal and normal casesmyalgia, malaise, headache and fevercasescases casescases and normal and responsecasesmyalgia, malaise, headache and fevercasescases fever, shortnesscasescasescasesmyalgia, malaise, headache and fevercasescasescasesmyalgia, malaise, headache and fevercasescasescasesmyalgia, malaise, headache and fevercasescasescasesmyalgia, malaise, headache and fevercasescasesmyalgia, malaise, headache and fevercasescasescasesmyalgia, malaise, headache and fevercasescasescasesmyalgia, malaise, headachecasescasescasesmyalgia, malaise, headachecasescasesmyalgia, malaise, headachecasescasesmyalgia, malaise, headachecasescasesmyalgia, mala, and fever, shutingcasescasesfelvatedLVEF hadacheAbnormNSAIDs, hadacheMeanCasesmyalgia, fever, chils, shortnesfelvated casesLVEF and casesAbnormNSAIDs, casesCases					BNT162b	214						Unknown		ed
Image: sparse	[20]						uays	<b>A</b> 1					Own	eu
ImageImageOme case mRNA- 1273ImageImageOme case mRNA- 1273Image <t< td=""><td></td><td></td><td>U</td><td></td><td>-</td><td></td><td></td><td></td><td>cubeb</td><td></td><td></td><td></td><td></td><td></td></t<>			U		-				cubeb					
Image: constraint of the section of the sectin of the section of the section of			5	male	one case			and fever		<50% in 3	normal			
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$										cases	in one			
2021 [34] age hemmean age (b.6.1 yearsof age maleBNT162b 2 in all cases malecases in one case37 days cases in one casefittigue, abdominal pain, fever, shortness of breathin all cases>50% in all casesal in 6 cases and in 2 cases2.36 daysLarson et al 2021 [35]USA eq tab years8 cases and mand mand yearsAll mand maleBNT162b 2 in 5 cases and 3 cases mRNA- 12732ai in 7 cases and 1s in 5 cases and 1s in one caseChest pain, malgia, fever, chills, shortness of breathElevated cases in all cases cases and cases and 1s cases of breathElevated cases and 1s in 2 cases cases and cases in 1 caseUVEF cases and 1s in 2 cases in 1 caseNSAIDs, col-hicine and prednisoneUNAn own ovnDeb et al 2021 [36]USA vears67 vearsMale mRNA- 12732mi N caseMaan 5.5 case case case case case orthopnea, fatigueElevated cases cases cases casesLVEF cases cases casesNormal casesintravenous furosemide, daysAbbate et al 2021 [36]USA vears67 vearsMale cases2mi N scond2mi N scondMaan 5.5 cases and 1s in one case case case case case caseFever, cough, case case case case caseUNKnow n nLVEF casesAbnorm casesPrednisone cases73 days for <td></td> <td></td> <td></td> <td></td> <td>1273</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>					1273									
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		USA										NSAIDs		Recover
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	2021 [34]			-			37 days							ed
Larson et al 2021 [35]USA and 			U						cases	cases			uays	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$					cuses			· ·						
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$			5								in 2			
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$											cases			
$ \begin{bmatrix} [35] \\ Ialy \\ symbol{sharp}{s} \\ [35] \\ [36] \\ [36] \\ [36] \\ [37] \\ [37] \\ [37] \\ [37] \\ [37] \\ [38] \\$								1 ·					-	Recover
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$							75 days						own	ed
Letyearsmale3 cases mRNA- 1273casecoughcoughnormal casesnormal in 1 casenormal in 1 case <t< td=""><td>[35]</td><td>Italy</td><td>0</td><td></td><td></td><td></td><td></td><td>· ·</td><td>cases</td><td></td><td></td><td>prednisone</td><td></td><td></td></t<>	[35]	Italy	0					· ·	cases			prednisone		
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$														
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$			years	marc		case		cougn						
2021 [36]WearsWearsImage1273ImageImageorthopnea, fatigueImageImageS50%ImageImagefurosemide, bronchodilatodaysAbbate et al 2021 [37]USA age age (30.5)2 cases and pearsOne mane al eBNT162b 2 in all cases2 <sup>nd</sup> in in one case and leMean 5.5 daysFever, cough, chest pain, nausea and vomitingUnknow nLVEF   solutionAbnorm al in all casesPrednisone days73 daysMuthuku mar et al 2021 [38]USA vears52 vearsMale nmRNA- 12732 <sup>nd</sup> 1 dayChest pain, fevers, shaking chills, myalgias, and headacheElevatedLVEF caseAbnorm alIow-dose lisinopril and carvedilol4 daysIsaak et al 2021 [39]Ger many years15 yearsMale BNT162b2 <sup>nd</sup> 1 dayfever, myalgia fever, myalgiaElevatedLVEF caseAbnorm alIow-dose lisinopril and carvedilol4 days										eases	in r cusc			
Abbate et al 2021 [37]USA age years2 cases maan and age secondOne in one cases2md in in one casesMean 5.5 daysFever, cough, chest pain, nausea and vomitingUnknow nLVEF <50% in in all casesAbnorm al in all casesPrednisone73 days days[37]USA age years2 cases mean and leBNT162b in one cases2md in in one caseMean 5.5 daysFever, cough, chest pain, nausea and vomitingUnknow nLVEF  sourceAbnorm all casesPrednisone days for one case73 daysMuthuku mar et al 2021 [38]USA vears52 vearsMale rmRNA- 12732md1 dayChest pain, fevers, shaking and headache and headacheLVEF sourceAbnorm all caseslow-dose lisinopril and carvedilol4 daysIsaak et al 2021 [39]Ger many years15 yearsMale BNT162b2md1 dayfever, myalgia fever, myalgiaElevatedLVEF sourceAbnorm alUnknown7 days	Deb et al	USA	67	Male	mRNA-	2 <sup>nd</sup>	1⁄4 day	Nausea,	Elevated	LVEF	Normal	intravenous	2	Recove
Abbate et al 2021 [37]USA mean age add 30.52 cases male age and age fema leOne male and 2 in all cases2md in in one case and 1st in second caseMean 5.5 daysFever, cough, chest pain, nausea and vomitingUnknow nLVEF  <50% in in all casesAbnorm al in all casesPrednisone days for one cases73 days daysMuthuku mar et al 2021 [38]USA vears52 vearsMale nmRNA- 12732 <sup>nd</sup> r1 dayChest pain, chest pain, rElevatedLVEF caseAbnorm al in all caseslow-dose lisinopril and carvedilol4 daysIsaak et al 2021 [39]Ger many15 yearsMale BNT162b2 <sup>nd</sup> r1 dayfever, myalgia fever, myalgiaElevatedLVEF caseAbnorm al caseslow-dose lisinopril and carvedilol4 days	2021 [36]		years		1273			orthopnea, fatigue		>50%			days	red
Abbate et al 2021 [37]USA mean age 30.5 years2 cases male and 0 ne fema leOne male and 2 in all cases2 md in in one case and 1st in second caseMean 5.5 daysFever, cough, chest pain, nausea and vomitingUnknow nLVEF <50% in in al in all casesAbnorm al in all casesPrednisone days for one caseMuthuku mar et al 2021 [38]USA years52 yearsMale mRNA- 1273mRNA- 12732nd and and1 day and caseChest pain, fevers, shaking chills, myalgias, and headacheElevatedLVEF and headacheAbnorm al in all casesIow-dose lisinopril and carvedilol4 daysIsaak et al 2021 [39]Ger many15 yearsMale BNT162b2 <sup>nd</sup> 1 dayfever, myalgiaElevatedLVEF comeAbnorm alIow-dose lisinopril and carvedilol4 days														
al 2021 [37]mean age 30.5male and age 30.5BNT162b 2 in all casesin one case and 1st in second casedays chest pain, nausea and vomitingn<50% in in all casesal in all casesdays for one casesMuthuku mar et al 2021 [38]USA r52 rMale rmRNA- 12732nd r1 dayChest pain, caseElevated rLVEF rAbnorm allow-dose lisinopril and carvedilol4 daysIsaak et al 2021 [39]Ger many15 yearsMale rBNT162b2nd r1 dayfever, myalgia rElevated rLVEF rAbnorm allow-dose lisinopril and carvedilol4 days	A 1-1	TICA	2	0		and in	M	E	I Indan and	LVEE	A 1		72	0
[37]age 30.5 yearsand one fema le2 in all casescase and 1st in second caseand vomiting and vomitingall casescasescasesfor one caseMuthuku mar et al 2021 [38]USA vears52 vearsMale rmRNA- 12732nd1 dayChest pain, fevers, shaking chills, myalgias, and headacheElevatedLVEF cone caseAbnorm allow-dose lisinopril and carvedilol4 daysIsaak et al 2021 [39]Ger many15 yearsMale BNT162b2nd1 dayfever, myalgia fever, myalgiaElevatedLVEF cone caseAbnorm alUnknown7 days		USA			BNT162b							Prednisone		One case
30.5 yearsone fema lecasesand 1st 							uays	1 .	11				-	died and
Image: second legender for a legender second l	[0,1]							und vonnung		un cuses	euses			one
Muthuku mar et al 2021 [38]USA52 yearsMale nmRNA- 12732nd 2nd1 day and and bChest pain, fevers, shaking chills, myalgias, and headacheElevated cond cond bLVEF cond alAbnorm lisinopril and carvedilol10w-dose lisinopril and carvedilol4 days daysIsaak et al 2021 [39]Ger many15 yearsMale BNT162b2nd1 dayfever, myalgiaElevatedLVEF cond condAbnorm allisinopril and carvedilol7 days													case	recover
Muthuku mar et al 2021 [38]USA years52 yearsMale nmRNA- 12732nd al1 day fevers, shaking chills, myalgias, and headacheElevated shaking chills, myalgias, and headacheLVEF solutionAbnorm allow-dose lisinopril and carvedilol4 daysIsaak et al 2021 [39]Ger many15 yearsMale BNT162b2nd1 dayfever, myalgiaElevatedLVEF solutionAbnorm allow-dose lisinopril and carvedilol4 days				le		second								ed
mar et al 2021 [38]years1273fevers, shaking chills, myalgias, and headache<50%allisinopril and carvedilolIsaak et al 2021 [39]Ger many15 yearsMale BNT162b2nd1 dayfever, myalgiaElevatedLVEF <50%														
2021 [38]  Image: Second structure  Image: S		USA		Male		2 <sup>nd</sup>	l day		Elevated				4 days	Recover
Isaak et al 2021 [39]  Ger many  15 years  Male BNT162b  2 <sup>nd</sup> 1 day  fever, myalgia  Elevated  LVEF Abnorm c50%  Unknown  7 days			years		1273					<50%	ai			ed
Isaak et al 2021 [39]Ger many15 yearsMale BNT162b2nd 2d1 dayfever, myalgiaElevatedLVEF s SAbnorm alUnknown7 days	2021 [30]							, , , , , , , , , , , , , , , , , , , ,				carveunor		
2021 [39] many years BNT162b <50% al	Isaak et al	Ger	15	Male		2 <sup>nd</sup>	1 dav		Elevated	LVEF	Abnorm	Unknown	7 days	Recover
					BNT162b	_		,						ed
			2		2									
		Italy		Male		2 <sup>nd</sup>	1 day	Chest pain	Elevated				7 days	Recover
al 2021 years 2 >50% al and ramipril			years		2					>50%	al	and ramipril		ed
[40]  Image: Constraint of the second secon		TIC A	20	Mol-	DNT1COL	and	2 dar-	Chast main 1	Elevet - 1	LVEE	Abnorm	Colobiaire	I Inl	Deserver
Watkins et al 2021USA20MaleBNT162b2nd2 daysChest pain and shortnessElevatedLVEFAbnormColchicine,Unknet al 2021years22shortness>50%almetoprolol,own		USA	-	wate		2	∠ uays	1	Elevated					Recover ed
	Ct al 2021		years		2					25070	u		own	cu
Chamling Ger 3 cases 2 BNT162b 1 <sup>st</sup> in 2 Mean 7 Chest pain Elevated LVEF Abnorm Unknown Unkn		Car	3 cases	2	BNT162b	1 <sup>st</sup> in 2	Mean 7		Elevated	LVEF	Abnorm	1	Unkn	Recover
et al 2021 many mean male 2 in 2 cases days in 2 case >50% in all al in 2 own	[41]	Ger				cases		* 						ed
[42] age s and cases, and and $2^{nd}$ and not cases cases	[41] Chamling et al 2021		mean	a and	cases, and					cases				
	[41] Chamling et al 2021		age				1		elevated		and	1	1	
	[41] Chamling et al 2021		age 37.66	1	ChAdOx1									
	[41] Chamling et al 2021		age 37.66	1 fema	nCoV-19	in l case			in 1 case		normal			
	[41] Chamling et al 2021		age 37.66	1							normal on 1			
	[41] Chamling et al 2021 [42]	many	age 37.66 years	1 fema le	nCoV-19 in 1 case	case	1 dav	Chest pain fever	in 1 case	LVFF	normal on 1 case	metoprolol	Mean	Recover
Mansour USA 2 cases 1 mRNA- 2 <sup>nd</sup> in 1 day Chest pain, fever, Elevated LVEF Abnorm metoprolol Mean	[41] Chamling et al 2021 [42] Mansour	many	age 37.66 years 2 cases	1 fema le 1	nCoV-19 in 1 case mRNA-	case 2 <sup>nd</sup> in	1 day	Chest pain, fever,	in 1 case Elevated		normal on 1 case Abnorm	metoprolol		Recover
Mansour et al 2021      USA      2 cases      1      mRNA-      2 <sup>nd</sup> in all      1 day      Chest pain, fever, in all      Elevated in all      LVEF      Abnorm al in all      metoprolol      Mean	[41] Chamling et al 2021 [42] Mansour et al 2021	many	age 37.66 years 2 cases mean	1 fema le 1 male	nCoV-19 in 1 case mRNA- 1273 in all	case 2 <sup>nd</sup> in all	1 day	Chest pain, fever,	in 1 case Elevated in all	>50% in all	normal on 1 case Abnorm al in all	metoprolol		Recover
Mansour et al 2021  USA  2 cases mean  1  mRNA- 1273 in all  2 <sup>nd</sup> in all  1 day  Chest pain, fever, in all  Elevated in all  LVEF  Abnorm al in all  metoprolol  Mean 2 days	[41] Chamling et al 2021 [42] Mansour et al 2021	many	age 37.66 years 2 cases mean age 23	1 fema le 1 male and 1	nCoV-19 in 1 case mRNA- 1273 in all	case 2 <sup>nd</sup> in all	1 day	Chest pain, fever,	in 1 case Elevated in all	>50% in all	normal on 1 case Abnorm al in all	metoprolol		

Levin et	Israel	7 cases	All	BNT162b	2 <sup>nd</sup> in	Mean 7	Chest pain,	Elevated	LVEF	Abnorm	Colchicine,	Mean	Recover
al 2021	151261	mean	of	2  in all	all	days	fatigue, fever and	in all	>50% in 5	al in all	Ibuprofen,	2.5	ed
[44]		age	them	cases	cases		headache	cases	cases LVEF	cases	Bisoprolol,	days	
		20.42	were						<50% in 2		and Ramipril		
		years	male			-			cases				
Schauer et	USA	13	12	BNT162b	2nd in	Mean 2.76	chest pain,	Elevated	LVEF	Abnorm	NSAIDs	Mean	Recover
al 2021		cases	male and 1	2 in all	all	days	shortness of breath, fever and	in all	>50% in 11 cases LVEF	al 1n 9		2 days	ed
[45]		mean age	fema	cases	cases		myalgia	cases	<50% in 2	cases and			
		15.07	le				inyaigia		cases	normal			
		years								in 4			
										cases			_
Shumkov a et al	Pola nd	23	Male	BNT162b 2	2 <sup>nd</sup>	1 day	chest pain, shortness of	Elevated	LVEF >50%	Abnorm al	Aspirin and methylprednis	6 days	Recover ed
2021 [46]	na	years		2			breath and fever		>30%	ai	olone		eu
Minocha	USA	17	Male	BNT162b	2 <sup>nd</sup>	2 days	chest pain	Elevated	LVEF	Abnorm	NSAIDs	6 days	Recover
et al 2021		years		2	_				>50%	al		<i>j</i> -	ed
[47]		-											
Hasnie et	USA	22	Male	mRNA-	1 <sup>st</sup>	3 days	Chest pain	Elevated	LVEF	Abnorm	Aspirin and	2 days	Recover
al 2021 [48]		years		1273					>50%	al	colchicine		ed
Starekova	USA	5 cases	4	BNT162b	2nd in	Mean 2,6	Chest pain,	Elevated	LVEF	Abnorm	Unknown	Unkn	Recover
et al 2021	Con	mean	male	2 in 3	all	days	fatigue, nausea,	in all	>50% in 4	al in 4	Chikhowh	own	ed
[49]		age	s and	cases and	cases	5	fever, chills and	cases	cases LVEF	cases			
		25.2	1	mRNA-			myalgia		<50% in 1	and			
		years	fema	1273 in 2					case	normal			
V .:	Terre	2	le All	cases mRNA-	21.1	Mean 2.5	Charteria	Elemente d	LVEF	in 1 case	NSAIDs	Maan	D
Koizumi et al 2021	Japa n	2 cases mean	of	1273 in all	2nd in all	days	Chest pain	Elevated in all	>50% in all	Abnorm al in all	INSAIDS	Mean 4 days	Recover ed
[50]	11	age	them	cases	cases	days		cases	cases	cases		+ days	cu
[50]		24.5	were	cubes	cubeb			cubeb	eases	euses			
		years	male										
McLean	USA	16	Male	BNT162b	2 <sup>nd</sup>	1 day	Chest pain	Elevated	LVEF	Abnorm	NSAIDs	7 days	Recover
et al 2021		years		2					>50%	al			ed
[51] Riedel et	Brazi	47	Male	Sinovac	2nd	Unknown	Chest pain Cough	Elevated	LVEF	Abnorm	Unknown	Unkn	Recover
al 2021	1	years	Wate	COVID-	2	UIKIIOWII	and myalgia	Lievaleu	<50%	al	Ulikilowii	own	ed
[52]	-	jeurs		19 vaccine			and myaigia			u		0.011	
				in									
				activated									
In-Cheol	Kore	24	Male	(China) BNT162b	2 <sup>nd</sup>	1 day	Chest pain	Elevated	LVEF	Abnorm	Unknown	5 daria	Recover
et al 2021	a	24 years	Male	2 BN11620	2""	1 day	Chest pain	Elevated	>50%	al	Unknown	5 days	ed
[53]	u	years		-					23070	ui			eu
Nguyen et	Ger	20	Male	mRNA-	1 <sup>st</sup>	1 day	Chest pain,	Elevated	LVEF	Abnorm	Unknown	Unkn	Recover
al 2021	many	years		1273			fatigue and		>50%	al		own	ed
[54]		70		<u> </u>	1 et	2.1	myalgia	<b>T</b> 1 1	LUED	. 1			D
Azdaki et al 2021	Iran	70 years	Male	ChAdOx1 nCoV-19.	1 <sup>st</sup>	3 days	Syncope	Elevated	LVEF >50%	Abnorm al	magnesium sulfate	7 days	Recover ed
[55]		years		neov-19.					25070	ai	suitate		cu
Sokolska	Pola	21	Male	BNT162b	1 <sup>st</sup>	3 days	Chest pain	Elevated	LVEF	Abnorm	Unknown	Unkn	Recover
et al 2021	nd	years		2		-	_		>50%	al		own	ed
[56]	LICA	5	A 11	DMT1 (A)	and : 4	M., 22	Chart	Elso ( 1	LVEE	A 1	C-1-1	м	Dee
Patel et al 2021 [57]	USA	5 cases mean	All of	BNT162b 2 in 4	2 <sup>nd</sup> in 4 cases	Mean 2.2 days	Chest pain, dyspena, nausea,	Elevated in all	LVEF >50% in all	Abnorm al in all	Colchicine, Ibuprofen and	Mean 1.8	Recover ed
2021 [37]		age	them	2 in 4 cases and	and 1 <sup>st</sup>	uays	headache and	cases	>50% in all cases	cases	aspirin	1.8 days	eu
		23.2	were	mRNA-	in 1		chills	00000	00000	00000	uspillin .	aayo	
		years	male	1273 in 1	case								
	-			case									-
Kim et al	Kore	29	Male	BNT162b	2 <sup>nd</sup>	1 day	Chest pain	Elevated	LVEF	Normal	corticosteroid	7 days	Recover
2021 [58]	а	years		2					>50%		s and NSAIDs.		ed
Ehrlich et	Ger	40	Male	BNT162b	1 <sup>st</sup>	6 days	chest pain and	Elevated	LVEF	Abnorm	Aspirin,	2 days	Recover
al 2021	many	years	maie	2		c aijo	shortness of	Lievated	<50%	al	heparin, beta-	_ 30,5	ed
[59]							breath, and fever				blocker and a		
											mineralocorti		
											coid		
	L										antagonist	l	

Schmitt et al 2021 [60]	Fran ce	19 years	Male	BNT162b 2	2 <sup>nd</sup>	3 days	Chest pain and dyspnea	Elevated	LVEF >50%	Abnorm al	Unknown	1 day	Recover ed
Kadwalw ala et al 2021 [61]	USA	38 years	Male	mRNA- 1273	1 <sup>st</sup>	2 days	Chest pain, fatigue and fever	Elevated	LVEF <50%	Abnorm al	Methylpredni solone, lisinopril, and spironolacton e	6 days	Recover ed
Azir et al 2021 [62]	USA	17 years	Male	BNT162b 2	2 <sup>nd</sup>	1 day	Chest pain	Elevated	LVEF >50%	Abnorm al	aspirin and sublingual nitroglycerin	1 day	Recover ed

# Table 2: Summary of pooled data from included research papers have been reported in the

literature (n = 147)

Age	Mean age - 28.94 years
Gender (n) %	Male – 138 (93.9%)
	Female – 9 (6.1%)
	Pfizer-BioNTech (BNT162b2) – 106 (72.1%)
	Moderna COVID-19 Vaccine (mRNA-1273) - 36 (24.5%)
Type of COVID-19 vaccine	Janssen (Johnson & Johnson) ( Ad26.COV2. S) – 2 (1.3%)
(n) %	Oxford, AstraZeneca COVID-19 vaccine ChAdOx1 nCoV-19 – 2
	(1.3%)
	Sinovac COVID-19 vaccine in activated – 1 (0.7%)
Dose (n) %	First dose – 19 (12.9%)
	Second dose – 128 (87.1%)
Days to symptom onset	Median 3.32 days
	Chest pain - 147 (100%)
Symptoms (n) %	Fever – 69 (46.9%)
	Myalgia/body aches – 80 (54.4)
	Shortness of breath – 11 (7.5%)
	Elevated – 145 (98.6%)
Troponin level (n) %	Not elevated – 1 (0.6%)
	Unknown – 1 (0.6%)
LVEF (n) %	LVEF >50% - 108 (73.5%)
	LVEF <50% - 39 (26.5%)
Electrocardiogram (ECG)	Abnormal – 130 (88.5%)
(n) %	Normal – 17 (11.5%)
Length of hospital stay	Median 5.2 days in 127 patients
(days)	Unknown in 20 patients
	Recovered – 137 (93.2%)
Outcome (n) %	Under follow-up – 7 (4.7%)
	Died – 3 (2%)